Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Party chief highlights development of private economic sector as lever for building prosperous Việt Nam 4.